Biomerieux SA
PAR:BIM

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
PAR:BIM
Watchlist
Price: 98.7 EUR 2.28% Market Closed
Market Cap: 11.6B EUR
Have any thoughts about
Biomerieux SA?
Write Note

Gross Margin
Biomerieux SA

55.7%
Current
57%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.7%
=
Gross Profit
2.1B
/
Revenue
3.8B

Gross Margin Across Competitors

Country FR
Market Cap 11.6B EUR
Gross Margin
56%
Country US
Market Cap 204.9B USD
Gross Margin
56%
Country US
Market Cap 195.2B USD
Gross Margin
67%
Country US
Market Cap 146.7B USD
Gross Margin
64%
Country US
Market Cap 132.6B USD
Gross Margin
69%
Country IE
Market Cap 110.6B USD
Gross Margin
66%
Country US
Market Cap 64.7B USD
Gross Margin
45%
Country DE
Market Cap 55.6B EUR
Gross Margin
38%
Country CN
Market Cap 319.2B CNY
Gross Margin
65%
Country US
Market Cap 41.6B USD
Gross Margin
79%
Country US
Market Cap 37.7B USD
Gross Margin
41%
No Stocks Found

Biomerieux SA
Glance View

Market Cap
11.6B EUR
Industry
Health Care

Show Overview: BioMérieux SA: Pioneering Diagnostics for a Healthier World BioMérieux SA, a French multinational founded in 1963, stands at the forefront of the global diagnostics industry, driving innovation in infectious disease testing and food safety. With a mission to improve public health through advanced diagnostic solutions, the company has developed a robust portfolio of products that include molecular biology, microbiology, and immunoassays. Its cutting-edge technologies empower healthcare professionals to detect pathogens with speed and accuracy, making a direct impact on patient outcomes and aiding in the prevention of disease outbreaks. By continuously investing in research and development, BioMérieux not only maintains its competitive edge but also expands its reach in emerging markets, balancing its operations with a strong commitment to sustainability and social responsibility. As health crises grow more complex and interconnected, BioMérieux's efforts to enhance diagnostic capacity have never been more critical. The company's recent forays into automation and artificial intelligence signal a shift toward more integrated and efficient testing systems, equipping laboratories and healthcare providers worldwide with the tools necessary to meet rising healthcare demands. Investors can see the potential for substantial returns not only through BioMérieux's innovative product offerings but also through its strategic partnerships and global expansion initiatives. With a solid financial foundation and a vision anchored in improving patient care, BioMérieux represents a compelling opportunity for investors looking to align with a company dedicated to making a meaningful difference in the health of communities across the globe.

BIM Intrinsic Value
103.48 EUR
Undervaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.7%
=
Gross Profit
2.1B
/
Revenue
3.8B
What is the Gross Margin of Biomerieux SA?

Based on Biomerieux SA's most recent financial statements, the company has Gross Margin of 55.7%.